Imaging Features of Primary Intracranial Sarcoma with Mutation: A Multicenter Case Series

Overview

Journal AJNR Am J Neuroradiol

Specialty Neurology

Date 2024 Apr 18

PMID 38637027

Authors

Rami W Eldaya

Richard J Fagan

Samir A Dagher

Angshumoy Roy

Sonika Dahyia

Gregory N Fuller

Max Wintermark

Matthew S Parsons

Thierry A G M Huisman

Affiliations

Soon will be listed here.

Abstract

Primary intracranial sarcoma, -mutant, is a rare, recently described entity in the fifth edition of the WHO Classification of CNS Tumors. Given the entity's rarity and recent description, imaging data on primary intracranial sarcoma, -mutant, remains scarce. In this multicenter case series, we present detailed multimodality imaging features of primary intracranial sarcoma, -mutant, with emphasis on the appearance of the entity on MR imaging. In total, 8 patients were included. In all 8 patients, the lesion demonstrated blood products on T1WI. In 7 patients, susceptibility-weighted imaging was obtained and demonstrated blood products. Primary intracranial sarcoma, -mutant, is a CNS neoplasm that primarily affects pediatric and young adult patients. In the present case series, we explore potential imaging findings that are helpful in suggesting this diagnosis. In younger patients, the presence of a cortical lesion with intralesional blood products on SWI and T1-weighted MR imaging, with or without extra-axial blood products, should prompt the inclusion of this entity in the differential diagnosis.

References

Rigsby R, Brahmbhatt P, Desai A, Bathla G, Ebner B, Gupta V . Newly Recognized CNS Tumors in the 2021 World Health Organization Classification: Imaging Overview with Histopathologic and Genetic Correlation. AJNR Am J Neuroradiol. 2023; 44(4):367-380. PMC: 10084895. DOI: 10.3174/ajnr.A7827. View

Wolf T, Coca A, Weingertner N, Chenard M, Meurgey A, Reita D . All pineal tumors expressing germ cell tumor markers are not necessarily germ cell tumors: histopathological and molecular study of a midline primary intracranial sarcoma DICER1-mutant. Virchows Arch. 2022; 482(2):431-435. DOI: 10.1007/s00428-022-03440-2. View

Merimsky O, LePechoux C, Terrier P, Vanel D, Delord J, Lecesne A . Primary sarcomas of the central nervous system. Oncology. 2000; 58(3):210-4. DOI: 10.1159/000012102. View

Tauziede-Espariat A, Hasty L, Metais A, Varlet P . Mesenchymal non-meningothelial tumors of the central nervous system: a literature review and diagnostic update of novelties and emerging entities. Acta Neuropathol Commun. 2023; 11(1):22. PMC: 9896826. DOI: 10.1186/s40478-023-01522-z. View

Kamihara J, Paulson V, Breen M, Laetsch T, Rakheja D, Shulman D . DICER1-associated central nervous system sarcoma in children: comprehensive clinicopathologic and genetic analysis of a newly described rare tumor. Mod Pathol. 2020; 33(10):1910-1921. DOI: 10.1038/s41379-020-0516-1. View

Louis D, Wesseling P, Aldape K, Brat D, Capper D, Cree I . cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol. 2020; 30(4):844-856. PMC: 8018152. DOI: 10.1111/bpa.12832. View

Louis D, Aldape K, Brat D, Capper D, Ellison D, Hawkins C . Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. Acta Neuropathol. 2016; 133(1):1-3. DOI: 10.1007/s00401-016-1646-x. View

Ripperger T, Bielack S, Borkhardt A, Brecht I, Burkhardt B, Calaminus G . Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. Am J Med Genet A. 2017; 173(4):1017-1037. DOI: 10.1002/ajmg.a.38142. View

Cardona A, Chamorro Ortiz D, Ruiz-Patino A, Gomez D, Munoz A, Ardila D . DICER1-associated central nervous system sarcoma: A comprehensive clinical and genomic characterization of case series of young adult patients. Neurooncol Pract. 2023; 10(4):381-390. PMC: 10346402. DOI: 10.1093/nop/npad014. View

10.

Sakaguchi M, Nakano Y, Honda-Kitahara M, Kinoshita M, Tanaka S, Oishi M . Two cases of primary supratentorial intracranial rhabdomyosarcoma with DICER1 mutation which may belong to a "spindle cell sarcoma with rhabdomyosarcoma-like feature, DICER1 mutant". Brain Tumor Pathol. 2019; 36(4):174-182. DOI: 10.1007/s10014-019-00352-z. View

11.

Lee J, Villanueva-Meyer J, Ferris S, Sloan E, Hofmann J, Hattab E . Primary intracranial sarcomas with DICER1 mutation often contain prominent eosinophilic cytoplasmic globules and can occur in the setting of neurofibromatosis type 1. Acta Neuropathol. 2019; 137(3):521-525. PMC: 6408274. DOI: 10.1007/s00401-019-01960-x. View

12.

Zhang G, Xiao B, Huang H, Zhang Y, Zhang X, Zhang J . Intracranial synovial sarcoma: A clinical, radiological and pathological study of 16 cases. Eur J Surg Oncol. 2019; 45(12):2379-2385. DOI: 10.1016/j.ejso.2019.08.015. View

13.

Diaz Coronado R, Mynarek M, Koelsche C, Mora Alferez P, Zambrano S, Wachtel Aptowitzer A . Primary central nervous system sarcoma with DICER1 mutation-treatment results of a novel molecular entity in pediatric Peruvian patients. Cancer. 2021; 128(4):697-707. DOI: 10.1002/cncr.33977. View

14.

Marinelli A, Cuomo M, Franca R, Buonaiuto M, Costabile D, Pagano C . A Rare Adult Primary Intracranial Sarcoma, -Mutant Identified by Epigenomic Profiling: A Case Report. Brain Sci. 2023; 13(2). PMC: 9953897. DOI: 10.3390/brainsci13020235. View

15.

Alexandrescu S, Meredith D, Lidov H, Alaggio R, Novello M, Ligon K . Loss of histone H3 trimethylation on lysine 27 and nuclear expression of transducin-like enhancer 1 in primary intracranial sarcoma, DICER1-mutant. Histopathology. 2020; 78(2):265-275. DOI: 10.1111/his.14217. View

16.

Brat D, Aldape K, Colman H, Holland E, Louis D, Jenkins R . cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". Acta Neuropathol. 2018; 136(5):805-810. PMC: 6204285. DOI: 10.1007/s00401-018-1913-0. View

17.

Louis D, Aldape K, Brat D, Capper D, Ellison D, Hawkins C . cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. Brain Pathol. 2016; 27(6):851-852. PMC: 8028991. DOI: 10.1111/bpa.12457. View

18.

Nejo T, Takayanagi S, Tanaka S, Shinozaki-Ushiku A, Kohsaka S, Nagata K . Primary Intracranial Spindle Cell Sarcoma, -Mutant, with Amplification Diagnosed on the Basis of Extensive Molecular Profiling. Clin Med Insights Case Rep. 2022; 15:11795476221131189. PMC: 9580084. DOI: 10.1177/11795476221131189. View

19.

Louis D, Giannini C, Capper D, Paulus W, Figarella-Branger D, Lopes M . cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol. 2018; 135(4):639-642. DOI: 10.1007/s00401-018-1826-y. View

20.

Ellison D, Hawkins C, Jones D, Onar-Thomas A, Pfister S, Reifenberger G . cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF mutation. Acta Neuropathol. 2019; 137(4):683-687. DOI: 10.1007/s00401-019-01987-0. View